Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Current Liabilities (2020 - 2025)

Tango Therapeutics has reported Total Current Liabilities over the past 6 years, most recently at $21.7 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $21.7 million for Q4 2025, down 43.2% from a year ago — trailing twelve months through Dec 2025 was $21.7 million (down 43.2% YoY), and the annual figure for FY2025 was $21.7 million, down 43.2%.
  • Total Current Liabilities for Q4 2025 was $21.7 million at Tango Therapeutics, up from $18.4 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for TNGX hit a ceiling of $55.5 million in Q4 2022 and a floor of $301964.0 in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $41.3 million (2021), compared with a mean of $37.5 million.
  • Biggest five-year swings in Total Current Liabilities: soared 36393.7% in 2021 and later crashed 50.92% in 2025.
  • Tango Therapeutics' Total Current Liabilities stood at $40.7 million in 2021, then skyrocketed by 36.51% to $55.5 million in 2022, then fell by 17.3% to $45.9 million in 2023, then fell by 16.91% to $38.2 million in 2024, then crashed by 43.2% to $21.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $21.7 million (Q4 2025), $18.4 million (Q3 2025), and $40.0 million (Q2 2025) per Business Quant data.